Imaging Biomarkers Market Size, Share and Growth Outlook, 2026

Imaging Biomarkers Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Imaging Biomarkers Market size is forecast to increase from $17.38 Billion in 2026 to $48.89 Billion in 2034 at a CAGR of 13.8% between 2026 and 2034.

The Imaging Biomarkers market report provides detailed analysis and outlook of Imaging Biomarkers segments including By Type (Functional Biomarkers, Morphological Biomarkers, Molecular Biomarkers, Metabolic Biomarkers), By Modality (Magnetic Resonance Imaging, Computed Tomography, Positron Emission Tomography, Single-Photon Emission Computed Tomography, Ultrasound), By Application (Oncology, Neurology, Cardiology, Musculoskeletal Disorders, Drug Discovery & Development), By End-User (Diagnostic Laboratories, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Imaging Biomarkers Industry Overview

Artificial Intelligence-Driven Imaging Biomarkers Transform Clinical Trial Endpoints

The imaging biomarkers industry is rapidly advancing as pharmaceutical companies and clinical research organizations increasingly adopt artificial intelligence-powered imaging technologies to generate objective and quantifiable measures of disease progression. Imaging biomarkers are becoming essential tools in modern drug development because they enable researchers to detect biological changes earlier than conventional clinical assessments. A significant industry milestone was achieved when Brainomix deployed its Brainomix 360 e-Lung platform for Boehringer Ingelheim’s Phase 3 DROP-FPF clinical trial in progressive pulmonary fibrosis. The study represents the first Phase 3 interstitial lung disease trial to formally incorporate automated quantitative high-resolution computed tomography imaging biomarkers as a co-primary endpoint. The technology analyzes subtle structural changes within lung tissue and provides objective measurements of treatment response, enabling investigators to assess therapeutic effectiveness before changes become visible through traditional lung function testing. This development highlights the growing role of imaging biomarkers in precision medicine, clinical endpoint evaluation, and respiratory disease research.

Advanced Analytics Platforms Enhance Neuroimaging Biomarker Assessment

The increasing complexity of neurological clinical trials is driving demand for sophisticated imaging biomarker analytics platforms capable of processing large-scale datasets with greater speed and accuracy. IXICO plc introduced IXI™ Version 10.0, the latest evolution of its artificial intelligence-powered neuroimaging data processing platform. The upgraded software incorporates advanced deep learning and machine learning technologies to support global clinical research programs focused on neurological disorders. Structural enhancements improve image upload efficiency, accelerate data processing workflows, and increase analytical precision for quantitative imaging biomarkers associated with Alzheimer’s disease and Parkinson’s disease progression. The platform also expands remote data-quality qualification capabilities across international trial locations, allowing sponsors to maintain consistent imaging standards throughout multicenter studies. As neuroscience research increasingly relies on quantitative imaging endpoints, advanced analytics solutions are becoming critical components of biomarker-driven drug development strategies.

Integrated Clinical Trial Ecosystems Support Scalable Biomarker Adoption

Strategic partnerships between imaging analytics providers and clinical trial technology companies are accelerating the integration of imaging biomarkers into mainstream pharmaceutical research workflows. IXICO strengthened its market position through a commercial and technical partnership with Medidata, a Dassault Systèmes company. The collaboration embeds IXICO’s specialized neuroimaging biomarker analytics directly into Medidata’s clinical trial management ecosystem, which supports a substantial proportion of active novel drug development programs. This integration enables biopharmaceutical companies to access automated imaging biomarker assessments within a centralized trial infrastructure, supporting faster decision-making during early-stage central nervous system research. The convergence of imaging analytics, artificial intelligence, and digital clinical trial platforms reflects a broader industry trend toward scalable, data-driven development models that improve operational efficiency and enhance the reliability of biomarker-based therapeutic evaluations.

Imaging Biomarkers Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Imaging Biomarkers market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Quanterix Corporation, Lantheus Holdings, Inc., Perspectum. The Imaging Biomarkers market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Imaging Biomarkers industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Imaging Biomarkers Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Imaging Biomarkers companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Imaging Biomarkers markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Imaging Biomarkers Market Competitive Benchmarking and Company Analysis

Leading companies in Imaging Biomarkers industry include- F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Quanterix Corporation, Lantheus Holdings, Inc., Perspectum. The Imaging Biomarkers market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Imaging Biomarkers Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Imaging Biomarkers market remains one of the strongest-performing segments in the country.
The US Imaging Biomarkers Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Imaging Biomarkers market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Imaging Biomarkers industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Imaging Biomarkers markets

Canada's strong Imaging Biomarkers sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Imaging Biomarkers market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Imaging Biomarkers Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Imaging Biomarkers market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Imaging Biomarkers population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Imaging Biomarkers industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Imaging Biomarkers market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Imaging Biomarkers sales through 2034

France Imaging Biomarkers companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Imaging Biomarkers Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Imaging Biomarkers distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Imaging Biomarkers Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Imaging Biomarkers market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Imaging Biomarkers industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Imaging Biomarkers industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Imaging Biomarkers Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Imaging Biomarkers market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Imaging Biomarkers market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Imaging Biomarkers Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Imaging Biomarkers Market Segmentation

By Type
Functional Biomarkers
Morphological Biomarkers
Molecular Biomarkers
Metabolic Biomarkers
By Modality
Magnetic Resonance Imaging
Computed Tomography
Positron Emission Tomography
Single-Photon Emission Computed Tomography
Ultrasound
By Application
Oncology
Neurology
Cardiology
Musculoskeletal Disorders
Drug Discovery & Development
By End-User
Diagnostic Laboratories
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes

Top Companies in Imaging Biomarkers Industry

F. Hoffmann-La Roche Ltd
Siemens Healthineers AG
GE HealthCare Technologies Inc.
Koninklijke Philips N.V.
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Quanterix Corporation
Lantheus Holdings, Inc.
Perspectum

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025